RecruitingNCT05326620

National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

PROspective Renal Cancer Cohort (PRO-RCC)

Sponsor

PROspective Renal Cancer Cohort Foundation

Enrollment

2,000 participants

Start Date

Jan 19, 2023

Study Type

OBSERVATIONAL

Conditions

Renal Cell Carcinoma Renal Cancer Renal Cell Cancer Metastatic

Summary

PRO-RCC is a nationwide long-term cohort for the collection of real-world clinical data, patient reported outcome measures (PROMs) and patient reported experience measures (PREMs) that provides an infrastructure for observational research and (randomized) interventional studies with the TwiCs (Trial within cohorts) design.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a national registry collecting long-term outcomes data from patients with renal cell carcinoma (kidney cancer), including treatment choices, surgical approaches, disease progression, and survival. **You may be eligible if...** - You have been diagnosed with renal cell carcinoma (kidney cancer) - You are being treated at a participating center - You are 18 or older - You consent to your data being included in the national registry **You may NOT be eligible if...** - You have a non-renal cell carcinoma kidney tumor (e.g., urothelial cancer) - You do not consent to data collection - You are not a patient at a participating center Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(27)

Amsterdam UMC locatie VUMC

Amsterdam, North Holland, Netherlands

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands

Meander Medisch Centrum

Amersfoort, Netherlands

Gelre ziekenhuis

Apeldoorn, Netherlands

Rijnstate

Arnhem, Netherlands

Amphia Ziekenhuis

Breda, Netherlands

Deventer Ziekenhuis

Deventer, Netherlands

Albert Schweitzer

Dordrecht, Netherlands

Catharina ziekenhuis

Eindhoven, Netherlands

Maxima MC

Eindhoven, Netherlands

Treant

Emmen, Netherlands

UMCG

Groningen, Netherlands

Spaarne Gasthuis

Haarlem, Netherlands

Tergooi MC

Hilversum, Netherlands

Medisch Centrum Leeuwarden

Leeuwarden, Netherlands

Maastricht UMC

Maastricht, Netherlands

St Antonius Ziekenhuis

Nieuwegein, Netherlands

Canisius Wilhelmina Ziekenhuis

Nijmegen, Netherlands

Bravis ziekenhuis

Roosendaal, Netherlands

Erasmus MC

Rotterdam, Netherlands

Maasstad ziekenhuis

Rotterdam, Netherlands

St. Franciscus ziekenhuis

Rotterdam, Netherlands

Haaglanden Medisch Centrum

The Hague, Netherlands

UMC Utrecht

Utrecht, Netherlands

Viecuri

Venray, Netherlands

Isala

Zwolle, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05326620

Related Trials

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402105 locations

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT000268841 location

DESTINY-PANTUMOUR04

NCT0712400017 locations

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT0614703715 locations

Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

NCT050232651 location